NCT02412423已完成4 期
Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- rate of acute GVHD
研究概览
简要总结
In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •haploidentical patients from maternal or collateral donors
排除标准
- •uncontrolled infection before transplant
研究组 & 干预措施
treatment group
Experimental
post-transplantation cyclophosphamide
干预措施: post-transplantation cyclophosphamide (Drug)
结局指标
主要结局
rate of acute GVHD
时间窗: participants will be followed for an expected average of 365 days
次要结局
- rate of relapse(participants will be followed for an expected average of 365 days)
- rate of non-relapse mortality(participants will be followed for an expected average of 365 days)
- probability of survival(participants will be followed for an expected average of 365 days)
研究者
Xiaojun Huang,MD
director
Peking University People's Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease ProphylaxisGVHDNCT06000982Shanghai Jiao Tong University School of Medicine138
进行中（未招募）
1 期
High doses of cyclophosphamide for prophylaxis of GVHD in patients undergoing allogeneic transplantatioEUCTR2017-003530-85-ITGITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA78
进行中（未招募）
3 期
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATGGraft Vs Host DiseasePeripheral Blood Stem Cell TransplantationMDS/MPNAMLMDSCMMLNCT05153226DKMS gemeinnützige GmbH640
已完成
2 期
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCTAcute Lymphoid LeukemiaMyelodysplastic SyndromesImmune System DiseasesAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaLymphomaNCT02294552Ivan S Moiseev200
Enrolling By Invitation
不适用
Post-transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Dose Reduction: 50 mg/kg vs 25 mg/kgGraft Vs Host DiseaseNCT05780554Centro de Hematología y Medicina Interna42